32nd week of 2009 patent applcation highlights part 34 |
Patent application number | Title | Published |
20090196861 | Biocompatible Latent Emulsifiers - A category of biocompatible dual-purpose emulsifiers for therapeutic and/or nutritional use is disclosed. The emulsifiers have at least two functions, which depend on pH and surrounding environment. In the anhydrous environment, they serve as nonionic solvents to dissolve the hydrophobic material, such as a hydrophobic drug or nutrient. When in the alkaline aqueous environment of the small intestine, they are transformed into a biocompatible ionic emulsifier. The emulsifiers can also be used to thin the surfactant/hydrophobe mixture in self-emulsifying bases and, thus, accelerate the emulsifying speed of the base without overloading the emulsifying capacity of the emulsion base. | 2009-08-06 |
20090196862 | High dosage Vitamin D - A preparation containing vitamin D | 2009-08-06 |
20090196863 | METHOD OF ANTIOXIDATION AND ANTIOXIDANT-FUNCTIONING WATER - A method of antioxidation and antioxidant-functioning water that can transform an antioxidation subject that is in an oxidation state due to a deficiency of electrons, or for which protection from oxidation is desired, into a reduced state where electrons are satisfied, by promoting the breaking reaction of molecular hydrogen that is used as a substrate included in hydrogen-dissolved water into a product of active hydrogen through a process employing a catalyst on the hydrogen-dissolved water, while anticipating high benchmarks of safety on the human body and reduced environmental burden. | 2009-08-06 |
20090196864 | INSECTICIDES THAT TARGET PROTEIN KINASE A (PKA) - The insecticides of the invention target the downstream portions of the signaling sequence of | 2009-08-06 |
20090196865 | Methods for the treatment and prevention of diseases of biological conduits - Methods for treating or preventing disease in biological conduits are provided herein. In certain embodiments, the methods relate to reducing or preventing vasospasm in blood vessel walls. In other embodiments, the methods described herein relate to reducing the accumulation of intimal hyperplasia in blood vessel walls after vascular procedures, including surgery. The methods encompass the use of agents that are useful for dilating biological conduits, but in dosages lower than are effective to achieve dilation of biological conduits. | 2009-08-06 |
20090196866 | Pharmaceutical composition containing an iron-binding agent - A pharmaceutical composition is disclosed. In at least one embodiment, a pharmaceutical drug is linked via a peptide linker to an iron-binding agent, for example an iron-binding protein, with the iron-binding agent in turn being bound to an iron-containing magnetic particle. The peptide linker has a protease recognition sequence, i.e. it may be cleaved at said protease recognition sequence by a protease, thereby enabling the pharmaceutical drug to be released locally. The pharmaceutical composition is suitable for magnetic drug targeting. | 2009-08-06 |
20090196867 | SOY KEFIR POWDER AND USES THEREOF - The invention provides a method for treating fatigue and/or mood disorders and/or improving satiety and/or vitality in a subject in need thereof, comprising the step of administrating an effective amount of a soy kefir powder to said subject. | 2009-08-06 |
20090196868 | METHODS AND COMPOSITIONS FOR PREVENTING RADIATION-INDUCED PNEUMONITIS - Disclosed are methods of minimizing the risk for a patient of developing pneumonitis during radiotherapy for a thorax-associated neoplasm and compositions for use in such methods. A preferred composition comprises a CD95/CD95L inhibitor. Further disclosed is a method of increasing the radiation dose administered to a patient during radiotherapy for a thorax-associated neoplasm. | 2009-08-06 |
20090196869 | ANTITUMOR COMBINATIONS CONTAINING TAXANE DERIVATIVES - The disclosure relates to pharmaceutical combinations comprising acetylcyclopropyl docetaxel and a monoclonal antibody against ErbB2, and to methods of use thereof. | 2009-08-06 |
20090196870 | BINDING CONSTRUCTS AND METHODS FOR USE THEREOF - The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins. | 2009-08-06 |
20090196871 | USE OF 4-PYRIDYLMETHYLPHTHALAZINES FOR CANCER TREATMENT - Patients suffering from renal carcinoma are treated with a 4-pyridylmethyl-phthalazine anti-angiogenesis agent. Patients having different tumor types, e.g. renal cancer, are treated with a 4-pyridylmethyl-phthalazine anti-angiogenesis agent while undergoing chemotherapy. | 2009-08-06 |
20090196872 | HUMAN MONOCLONAL ANTIBODIES TO INFLUENZA M2 PROTEIN AND METHODS OF MAKING AND USING SAME - Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. A human monoclonal antibody that binds to influenza M2 protein having different amino acid sequences. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject. | 2009-08-06 |
20090196873 | Methods and compositions for treating diseases targeting CDCP1 - Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of CDCP1 in disease cells compared to healthy cells. Also provided are antagonists or agonists of CDCP1, and methods for screening agents that modulate the CDCP1 level or activity in vivo or in vitro. | 2009-08-06 |
20090196874 | ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS - The invention involves the detection of virally infected cells by antibodies or antibody fragments which selectively bind to TSG101. TSG101 is on the surface of mammalian cells, and thus available for detection by antibodies, during viral budding—a phenomenon wherein viral particles escape a virally infected cell after propagation in that cell, so as to infect other cells. To achieve budding, a protein, TSG101 is “hijacked” and misdirected to, or mis-expressed on, the surface of the infected cell. Antibodies can be used to selectively detect such infected cells. Certain TSG101 antibodies may provide therapeutic benefit when administered to infected mammals. | 2009-08-06 |
20090196875 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 2009-08-06 |
20090196876 | Novel Gene Disruptions, Compositions and Methods Relating Thereto - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331, PRO354, PRO355, PRO533, PRO541, PRO725, PRO937, PRO1014, PRO1120, PRO1182, PRO1325, PRO1382, PRO1410, PRO1555, PRO1556, PRO1760, PRO1787, PRO1868, PRO4326, PRO4332, PRO4346, PRO4400, PRO6003, PRO6094, PRO6244, PRO9820, PRO9828, PRO10274, PRO16090, PRO19644, PRO21340, PRO92165, PRO85143, PRO1124, PRO1026 or PRO23370 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. | 2009-08-06 |
20090196877 | Novel Method to Increase Memory T Lymphocytes and Enhance Their Functions - The invention generally features compositions and methods that are useful for increasing immune function. Such methods can be employed to enhance innate immunity for the prevention or treatment of pathogen infections (e.g., bacterial, viral, or fungal infections), lymphopenia, or cancer by stimulating a CD1 37 polypeptide expressed on an immune cell, such as a memory T cell. The invention further comprises a mouse lacking detectable levels of CD 137, cells derived from the mouse, and methods of producing additional knockouts animals. | 2009-08-06 |
20090196878 | Intestinal epithelial glucose sensor - The present invention relates to a mammalian intestinal epithelial glucose sensor; more specifically to a human intestinal epithelial glucose sensor. The invention relates further to the use of this sensor to modulate or monitor intestinal carbohydrate uptake and metabolism and to the use of ligands and/or inhibitors and/or activators of this sensor to treat or prevent diseases such as diabetes and obesity, and to provide nutritional aids for the elderly, infants and athletes. | 2009-08-06 |
20090196879 | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome - The present invention relates in a first aspect to a B-cell depleting anti-CD20 antibody or a CD20-binding antibody fragment thereof for the treatment of chronic fatigue syndrome and myalgic encephalomyelitis. In particular, the present invention relates to the use of anti-CD20 monoclonal antibodies or fragments thereof which are preferably humanized for the treatment of chronic fatigue syndrome/myalgic encephalomyelitis in a subject afflicted with said disease. | 2009-08-06 |
20090196880 | Cancer treatment using humanized antibodies that bind to EphB4 - In certain embodiments, this application provides humanized antibodies that bind to the EphB4 protein as well as uses of the antibodies for therapeutic purposes. | 2009-08-06 |
20090196881 | DNA vaccine against north american spring viremia of carp virus - In this application is described a novel DNA vaccine for Spring viremia of carp virus. The candidate vaccine a SVCV glycoprotein (G) gene from the North Carolina isolate. The DNA vaccine provides protection in vaccinated fish against challenge with the SVCV. | 2009-08-06 |
20090196882 | METHODS OF PRODUCING ANTIBODIES TO ZALPHA11 CYTOKINE RECEPTORS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 2009-08-06 |
20090196883 | Plasmodium vivax hybrid circumsporozoite protein and vaccine - Described in this application is a synthetic | 2009-08-06 |
20090196884 | Malaria Vaccines - The present invention relates to a synthetic antigenic sequence which represents a combination of epitope-containing sequences from the highly polymorphic block 2 repeat region of K1-type | 2009-08-06 |
20090196885 | Cancer Treatment - This invention relates to a method of treating cancer by administering to a subject in need thereof an effective amount of a mevalonate pathway inhibitor and an effective amount of an | 2009-08-06 |
20090196886 | VACCINE AGAINST NICOTINE ADDICTION - The present invention provides a hapten in the form of a novel nicotine derivative that may suitably be conjugated with an appropriate carrier to yield an effective vaccine against nicotine addiction. More particularly, the invention relates to a nicotine derivative of the following formula (I): | 2009-08-06 |
20090196887 | Immunogenic Compositions for Activating Gamma Delta T Cells - Disclosed are compositions, kits, and methods for activating, expanding, or stimulating γδ T cells that include recombinant attenuated microbes. The compositions may include pharmaceutical compositions that are used as γδ T cell stimulating vaccines or immunogenic compositions for preventing or treating microbial infections and hyperplasias such as cancer. | 2009-08-06 |
20090196888 | Nucleic acids encoding recombinant 56 and 82 kDa antigents from gametocytes of Eimeria maxima and their uses - The present invention provides the recombinant cloning and sequencing of two of the major | 2009-08-06 |
20090196889 | CONTROLLED ABSORPTION OF STATINS IN THE INTESTINE - The present invention provides a controlled absorption formulation in which modified release of active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient into the body of the subject than can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core over which an outer coating is layered. The core is optionally and preferentially in the form of a tablet. | 2009-08-06 |
20090196890 | PHARMACEUTICAL COMPOSITIONS - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 2009-08-06 |
20090196891 | PROCESS FOR PREPARING WATER SOLUBLE ARTICLES - A process for preparing a water-soluble article comprising a water-soluble primary thermoformed component and a water-soluble secondary component arranged therein comprises:
| 2009-08-06 |
20090196892 | PROCESS FOR PREPARING WATER SOLUBLE ARTICLES - A process for preparing a water-soluble article comprising a water-soluble primary thermoformed component and a water-soluble secondary component arranged therein comprises:—
| 2009-08-06 |
20090196893 | Aqueous Cosmetic Composition, Especially for Use as Moisturizing Lotions - The invention relates to the use of an aqueous composition comprising at least one surface-active agent in the form of bilayers and exhibiting a structure of sponge phase type as cosmetic composition or for the preparation of a cosmetic composition. | 2009-08-06 |
20090196894 | Self Tanning Composition - Disclosed is a method for the colouration of skin or a keratinic fibre, characterized in that the skin or keratinic fibre is contacted with a formulation containing a dispersion of solid particles of a tanning substance selected from a compound of the formula (I) wherein i is 0 or 1 and each of R | 2009-08-06 |
20090196895 | COSMETIC PREPARATION COMPRISING AN ANTI-AGING SKIN CARE COMPLEX - The invention relates to a cosmetic preparation which includes a skin care complex having an anti-ageing effect. The complex consists of liposomes comprising a mixture of cosmetic oil, extract of | 2009-08-06 |
20090196896 | ANTIMICROBIAL AGENT TO INHIBIT GROWTH OF MICROORGANISMS ON DISPOSABLE PRODUCTS - The present disclosure relates to an article having a fiber including an antimicrobial agent to inhibit growth of microorganisms. The article inhibits the growths of microorganisms in biological, physiological fluids, and non-biological solutions. The article includes a fibrous structure and silver halide particles applied to the fibers to inhibit the growth of the microorganism. | 2009-08-06 |
20090196897 | TWO PART CHEMICAL CONCENTRATE - The invention is a solid chemical concentrate system of at least two cooperative shapes. The first shape is an inwardly curved bar having an inner opening. The second shape is an insert which is capable of interlocking with the bar by insertion into the bar inner opening. The solid chemical concentrate provides chemical systems having active constituents which may be the same, different but compatible or functionally and chemically incompatible combined within one matrix to provide at least one substantially continuous surface. The system may also comprise an aqueous soluble or dispersible polymeric film cover. | 2009-08-06 |
20090196898 | STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED - Bioimplants and methods of making the bioimplants are provided. The bioimplants comprise biological tissues having conjugated thereto adjunct molecules. The biological tissues are sterilized with a chemical sterilizing agent, such as a water soluble carbodiimide. The processes of making the bioimplants include a process in which an adjunct molecule is conjugated to a biological tissue during the sterilization process. | 2009-08-06 |
20090196899 | Controlled Alloy Stent - A method of manufacturing a stent includes determining a porosity characteristic and combining at least two predetermined alloy constituents based on the porosity characteristic. The method further determines a solidification profile based on the porosity characteristic and combined alloy constituents and solidifies the combined alloy constituents based on the solidification profile. In addition, the method includes forming a stent framework from the solidified alloy constituents, removing at least a portion of at least one of the alloy constituents, and forming pores within the stent framework based on the removal and consistent with the porosity characteristic. | 2009-08-06 |
20090196900 | Use of Phosphodiesterase Inhibitor as a Component of Implantable Medical Devices - Implantable medical devices having coatings comprising phosphodiesterase inhibitors are disclosed. Specifically, coatings comprising phosphodiesterase-5 inhibitors are disclosed. The phosphodiesterase-5 inhibitors include sildenafil, tadalafil, vardenafil or pharmaceutically acceptable derivatives thereof. The medical devices can include stents, catheters, micro-particles, probes and grafts | 2009-08-06 |
20090196901 | Tissue Engineering Methods and Compositions - The presently disclosed subject matter generally relates to methods and systems for facilitating the growth and differentiation of adipose-derived stem cells for laboratory and therapeutic applications. The cells can be employed alone or in conjunction with unique biologically-compatible scaffold structures to generate differentiated tissues and structures, both in vitro and in vivo. The presently disclosed subject matter further relates to methods of forming and using improved tissue engineered scaffolds that can be used as substrates to facilitate the growth and differentiation of cells. | 2009-08-06 |
20090196902 | BIOGENERATOR CONSTRUCTED USING LIVE CELL CULTURES - An apparatus (or a biogenerator) is disclosed which utilizes the electrochemical polarization of epithelial cells to generate electricity. The apparatus employs living cells to convert chemical energy into electricity. The biogenerator is capable of supplying electricity to other devices continuously for extended periods of time. Because the apparatus may be made sufficiently small for implantation into the body of an animal or a human, such an apparatus is particularly useful for powering devices that require implantation into the host body. | 2009-08-06 |
20090196903 | DRUG DELIVERY DEVICES, KITS AND METHODS THEREFOR - Implantable drug delivery devices, and kits and methods incorporating them are described. The devices may, for example, be configured for implantation into an ocular region of a subject. The drug delivery devices may comprise multiple, selectively-triggerable drug reservoirs for administration of sequential or concomitant drug regimens. Some variations of devices may comprise one or more reservoirs that may be triggered by an optical stimulus, e.g., light having a wavelength within a certain wavelength range. The devices, methods, and kits may be useful in the treatment chronic ocular conditions, such as age-related macular degeneration. | 2009-08-06 |
20090196904 | HIGHLY-MINERALIZED OSTEOGENIC SPONGE COMPOSITIONS AND USES THEREOF - Osteogenic sponge compositions having enhanced osteoinductive properties for use in bone repair are described. The compositions include a quickly resorbable porous carrier, a more slowly resorbed mineral scaffold and an osteogenic factor, preferably a bone morphogenetic protein. The compositions enable increased osteoinductive activity while retaining a reliable scaffold for the formation of new bone at an implant site. Methods for therapeutic use of the compositions are also described. | 2009-08-06 |
20090196905 | STABILIZATION OF MITOCHONDRIAL MEMBRANES IN OCULAR DISEASES AND CONDITIONS - Methods of treating ocular diseases and conditions using biodegradable ocular implants containing cyclosporine to inhibit mitochondrial permeability transition pore formation are disclosed. | 2009-08-06 |
20090196906 | Kinase inhibitors - The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed. | 2009-08-06 |
20090196907 | EDIBLE FILM-STRIPS FOR IMMEDIATE RELEASE OF ACTIVE INGREDIENTS - The present invention is directed to an edible film that contains two or more segmented portions and comprises an active ingredient that is distributed on a segmented portion or portions which comprise less than 50% of the cross sectional surface area of a major face of said film. The present invention also relates to methods of treatment for the treatment of various conditions and for taste-masking of pharmaceutical ingredients. | 2009-08-06 |
20090196908 | EDIBLE FILM-STRIPS WITH MODIFIED RELEASE ACTIVE INGREDIENTS - The present invention is directed to an edible film that contains a modified release active ingredient. The active ingredient may be present in the edible film a variety of forms, including a modified release matrix, in a modified release particulate form, in microgel liquid filled beads or in a bilayer film. The present invention also includes edible films which comprise additional immediate release active ingredients. | 2009-08-06 |
20090196909 | CARBON NANOTUBE CONTAINING MATERIAL FOR THE CAPTURE AND REMOVAL OF CONTAMINANTS FROM A SURFACE - There is disclosed an article and method of making an article for removing at least one contaminant from a solid surface. In one embodiment, the article comprises carbon nanotubes attached to a support media, such as a nonwoven mixture of PET and cotton. There is also disclosed a method of removing at least one contaminant from a solid surface, such as areas where microbial, particle, or static contamination is undesirable, including hospitals, clean rooms, kitchens, baths, or human hands. | 2009-08-06 |
20090196910 | Sustained-Release Preparation of Statin Drugs - A preparation of statins for prolonged release. The preparation is a transdermal therapeutic system or hypodermic implantation system. And they overcome the problem of low bioavailability and increase patient compliance. The statins in the invention contain all of statins and responding salts, hydroxyl ester derivatives at 4-position. The invention has many advantages: for example, reduce dosage frequency, remain stable and lasting blood concentration of medicine, further improve the curative effect, provide patients with a convenient and safety means of administration, and obtain an effective period of up to seven days to months by taking medicine once. | 2009-08-06 |
20090196911 | Silicone Acrylate Hybride Composition and Method Of Making Same - A silicone acrylate hybrid composition includes the reaction product of a silicon-containing pressure sensitive adhesive composition, an ethylenically unsaturated monomer, and an initiator. The silicon-containing pressure sensitive adhesive composition includes acrylate or methacrylate functionality. A method of making the hybrid composition includes polymerizing the ethylenically unsaturated monomer and the silicon-containing pressure sensitive adhesive composition in the presence of the initiator. | 2009-08-06 |
20090196912 | Pyridinylamines - Described are pyridinylamines and pharmaceutically acceptable salts thereof, the use of these pyridinylamines for the prophylaxis and/or treatment of various diseases such as infectious diseases, including opportunistic infections, prion diseases immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as pharmaceutical compositions containing at least one pyridinylamine and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the pyridinylamines are disclosed. | 2009-08-06 |
20090196913 | Anti-Alpha-V Immunoliposome Composition, Methods, and Uses - An immunoliposome composition targeted to the alpha-V-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha-V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or a the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent. | 2009-08-06 |
20090196914 | LIPOSOMAL L-CARNITINE - The present invention provides liposomal L-carnitine formulations and methods for the treatment of intermittent claudication. The formulation is optimized with respect to L-carnitine transport through skin in vitro. Preferably, the formulation is a topical cream for the administration of the drug directly on the muscle group that is most affected by the poor local blood flow. | 2009-08-06 |
20090196915 | COMPOSITION AND METHODS OF MAKING AND USING INFLUENZA PROTEINS - The invention provides compositions of influenza proteins, such as matrix and nucleoprotein, that are presented to an individual's immune system as multimeric displays to induce an immune response. The compositions are optionally associated with any type of immunomodulatory compound (IMC) comprising an immunostimulatory sequences (ISS). The invention further provides compositions of influenza matrix and nucleoproteins that can induce cellular and/or humoral immune response. The invention also provides methods of making and using these compositions, e.g., as a vaccine, for ameliorating symptoms associated with infection with influenza virus or for reducing the risk of infection with influenza virus. | 2009-08-06 |
20090196916 | Liposome-mediated ligation - Chemoselective ligation of hydrophobic reactants in a lipid phase. | 2009-08-06 |
20090196917 | Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions - Disclosed herein is a liposomal formulation that comprises a liposome and a liquid carrier. In the liposomal formulation, the liposome comprises a hydrophobic lactone drug and has an intraliposomal metal ion concentration higher than the metal ion concentration of the liquid carrier. Also disclosed herein is a method for active loading of a hydrophobic lactone drug into a liposome. The method includes preparing a liposome in the presence of a metal salt solution, an acid form of a counterion of the metal salt being membrane permeable, such that the liposome preparation contains entrapped metal ion. The method further includes forming a liposome with high intraliposomal pH by separating extravesicular metal salt solution from the liposome by exposing the liposome to a metal salt-free solution, resulting in diffusion of the acid form of the counterion out of the liposome and formation of an intraliposomal pH higher than that of the metal salt-free solution. The method also includes exposing the liposome with high intraliposomal pH to an isoosmolal solution containing a hydrophobic lactone drug, the isoosmolal solution having a pH lower than the intraliposomal pH, such that the hydrophobic lactone drug accumulates in the liposome predominantly in its ring-opened form. | 2009-08-06 |
20090196918 | Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions - Provided is a liposome comprising a hydrophobic lactone drug and a cyclodextrin, wherein the liposome has an intraliposomal pH and cyclodextrin concentration such that upon administration of the liposome to a subject, the liposome exhibits a uniform release profile of the hydrophobic lactone drug. Also provided is a method of administering a hydrophobic lactone drug to a subject in need thereof. The method comprises administering a liposome to the subject in need, wherein the liposome comprises the hydrophobic lactone drug and a cyclodextrin. The liposome has an intraliposomal pH and cyclodextrin concentration such that upon administration of the liposome to the subject, the liposome exhibits a uniform release profile of the hydrophobic lactone drug. | 2009-08-06 |
20090196919 | OXCARBAZEPINE DOSAGE FORMS - The present invention relates to dosage forms of oxcarbazepine for oral administration that contain oxcarbazepine having a median particle size of from about 14 μm to about 30 μm and to processes for the preparation of such dosage forms. The dosage form may be a solid or a liquid dosage form. The solid dosage form may be in the form of a tablet, a capsule, or a granulate. The liquid dosage form may be in the form of a solution or a suspension. | 2009-08-06 |
20090196920 | PHARMACEUTICAL COMPOSITION COMPRISING MICROCAPSULES OF STATINS SUSPENDED IN ALKYL ESTERS OF POLYUNSATURATED FATTY ACIDS (PUFA) - The invention relates to a pharmaceutical composition comprising a suspension consisting of an oil with a high concentration of alkyl esters of polyunsaturated fatty acids (PUFA) and to microcapsules comprising at least one polymer and a statin. | 2009-08-06 |
20090196921 | Compositions Methods and Kits For Enhancing Immune Response To A Respiratory Condition - Disclosed herein are compositions for treating a respiratory condition, preferably by enhancing immune response in a mammal, the compositions including a therapeutic amount of a probiotic strain of bacteria and a therapeutic amount of an additional component. Also included are methods of treating a respiratory condition, preferably by enhancing immune response, in a mammal. Kits containing the compositions, and instructions for applying the methods are also included. The method includes orally administering to the mammal a therapeutic amount of a probiotic strain of bacteria and a therapeutic amount of an additional component. | 2009-08-06 |
20090196922 | BILAYER TABLET FOR PREVENTING CARDIOVASCULAR EVENTS - The present invention relates to a bilayer tablet which comprises a compartment containing a pharmaceutically acceptable simvastatin compound as its active ingredient; and at the same time a separate compartment containing a pharmaceutically acceptable lisinopril compound and a pharmaceutically acceptable folic acid compound as active ingredients, for the prevention of stroke in high-risk conditions or diseases. | 2009-08-06 |
20090196923 | CONTROLLED RELEASE FORMULATION COMPRISING ANTI-EPILEPTIC DRUGS - The present invention relates to pharmaceutical formulation of antiepileptic drug preferably oxcarbazepine. The formulation comprises multiple tablets or pellets of immediate release or controlled release nature, which are filled, inside the capsule to provides drug effect for 24 hours and is suitable for once a day administration. The patent also provides process of preparation of the dosage form. | 2009-08-06 |
20090196924 | CONTROLLED-RELEASE LAMOTRIGINE FORMULATIONS - Pharmaceutical controlled-release formulations comprising particles comprising lamotrigine or a pharmaceutically acceptable salt thereof, coated with a modified-release coating comprising a modified-release coating agent and a pore-former. | 2009-08-06 |
20090196925 | NATURAL PRODUCT COATING FOR TABLETS - An all-natural tablet coating composition comprised entirely of Certified Organic ingredients and organic compliant ingredients which can be applied to a compressed tablet core using conventional film coating techniques is provided. The coating is useful for preparing organic dietary supplements in a coated tablet form that exhibits good physical and chemical stability, good aesthetics, and which is free of synthetic materials. | 2009-08-06 |
20090196926 | NANO-STRUCTURED THIXOTROPIC INORGANIC PEELING GELS - A composition, a method, and a kit are provided for chemical skin peeling, based on nano-structured thixotropic inorganic gels, which have a higher potency and are less irritant of the conventional peeling formulations. The gels of the invention can easily be applied on the skin, where they form a stable, uniform layer, that doesn't strain. The kit comprises by a defatting gel, different types of peeling gels and a neutralizing gel. The defatting gel is characterized by a markedly enhanced defatting capacity in comparison to the conventional products, because the sebum solubilized by the solvent is strongly adsorbed on the huge surface of the nano-structured material of the gel. The peeling gels are based on conventional peeling compounds, such as glycolic acid, trichloroacetic acid, pyruvic acid, salicylic acid, Jessner solution, but the presence of nano-structured material strongly increases the peeling effect, allowing the use of lower concentrations of peeling compound, with only minimal skin irritation for the user. The neutralizing gel is characterized by a colour change that allows the operator to verify in real time the neutralization of the peeling agent on the treated skin surface. All the gels of the invention can be easily removed from the skin after the treatment. The thixotropic gels of the invention can be used in chemical skin peeling for the treatment of various cosmetic conditions and dermatological disorders, including dry skin, acne, dandruff, keratoses, age spots, wrinkles and disturbed keratinisation. | 2009-08-06 |
20090196927 | Polypeptide Inhibitors of HSP27 Kinase and Uses Therefor - The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses. | 2009-08-06 |
20090196928 | Biocompatible hydrogel compositions - Compositions, instruments, systems, and methods are providing for creating families of materials having diverse therapeutic indications and possessing enhanced biocompatibility. One genus platform for the families includes a biocompatible synthetic electrophilic component mixed with a nucleophilic component. The electrophilic component can include a functionalized electrophilic poly (anhydride ester) material. The nucleophilic material can include a natural, autologous protein. The components, when mixed in a liquid state, react by cross-linking, forming a solid matrix composition, or hydrogel. | 2009-08-06 |
20090196929 | Silica Wetcake Treatment Method - New methods of treating silica wetcake during precipitated silica materials manufacturing are provided. Such methods permit a significant increase in high solids content processing while simultaneously reducing high viscosity of the resultant particles for transport facilitation. The resultant precipitated silica wetcake is treated with a borate-containing dispersant to impart the necessary low viscosity characteristics thereto. Such a dispersant accords not only such a viscosity result, but will not char or otherwise discolor the silica particles during evaporation of the liquids within the wetcake itself. Furthermore, such a dispersant, if left on the surfaces of such particles, will not deleteriously affect the abrasivity, fluoride compatibility, or other dentifrice properties of the precipitated silica materials themselves. Also encompassed within this invention are the resultant precipitated silica particles exhibiting borate residues and dentifrices including such materials. | 2009-08-06 |
20090196930 | AEROSOLIZED NITRITE AND NITRIC OXIDE -DONATING COMPOUNDS AND USES THEREOF - Disclosed herein are formulations of nitrite, nitrite salt, or nitrite- or nitric oxide-producing compounds suitable for aerosolization and use of such formulations for aerosol administration of nitrite, nitrite salt, or nitrite- or nitric oxide-donating compounds for the treatment of pulmonary arterial hypertension, intra-nasal or pulmonary bacterial infections, or to treat or prevent ischemic reperfusion injury of the heart, brain and organs involved in transplantation. In particular, inhaled nitrite, nitrite salt, or nitrite- or nitric oxide-donating compound specifically formulated and delivered to the respiratory tract for the indications is described. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures and manufacturing processes for production and use of the compositions described. | 2009-08-06 |
20090196931 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS - Methods are provided for inhibiting or treating stenosis or restenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective amount of a therapeutic agent via a catheter. Also provided is a catheter adapted for administering a therapeutically effective amount of a therapeutic agent to a mammalian host for inhibiting or treating stenosis or restenosis. | 2009-08-06 |
20090196932 | PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN - A dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof, as well as a dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical composition. | 2009-08-06 |
20090196933 | COMPOSITIONS AND METHODS FOR PREPARATION OF POORLY WATER SOLUBLE DRUGS WITH INCREASED STABILITY - The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration. | 2009-08-06 |
20090196934 | SPHERICAL ELEMENTARY GRANULE AND METHOD FOR PRODUCTION THEREOF - The characteristic in being coated with film of spherical elementary granules is improved by adjusting a short/long diameter-ratio distribution coefficient to a specific value. | 2009-08-06 |
20090196935 | Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets - The present invention is directed to pharmaceutical capsules comprising extended release formulations of dipyridamole, processes for preparing such dipyridamole extended release formulations and their use in the treatment of stroke. | 2009-08-06 |
20090196936 | Hydrogel wound dressing and biomaterials formed in situ and their uses - The present invention relates to a method of forming shape-retentive and shape-conforming aggregate wound dressings and biomaterials composed of gel nanoparticles and wound or bodily fluid in which the aggregates are held together by non-covalent bond physical forces such as, without limitation, hydrophobic-hydrophilic interactions and hydrogen bonds. The method comprises introducing a dry powder of gel nanoparticles to a wound site in which the nanoparticles absorb some of the blood or wound exudate and coalesce in situ into the claimed shape-retentive aggregate dressing. The method also comprises introducing the dry nanoparticle powder in or on a wet bodily tissue in vivo to form the claimed shape-retentive biomaterial. In addition, the method also comprises incorporating biomedical agents to produce medicated aggregate dressings or biomaterials for a variety of medical applications. This invention also relates to uses of the method of formation of the shape-retentive aggregates of gel nanoparticles. | 2009-08-06 |
20090196937 | TEMPERATURE-SENSITIVE NANO-CARRIERS - The present invention relates to a process of preparing a biocompatible temperature-sensitive nano-carrier, which comprises the steps of (a) preparing a polymer dispersion comprising a water-soluble biocompatible polymer with photo-crosslinkable functional group(s), (b) preparing a polymer-initiator solution by adding an initiator to the polymer dispersion, and (c) preparing the nano-carrier by irradiating light onto the polymer-initiator solution, wherein the average diameter of the nano-carrier changes depending on temperature, and also relates to a temperature-sensitive nano-carrier. Nano-carriers of the present invention are temperature-sensitive, and their average diameter and pore size reversibly change in response to temperature change. In an embodiment of the present invention, nano-carriers can be prepared via a one-pot single-phase synthesis. A process of the present invention overcomes the conventional problems such as the use of organic solvent, complicated preparation steps, a relatively high manufacture cost and a low loading efficiency. Moreover, a process of the present invention can ensure the stability of drugs without necessitating high-speed homogenization or ultrasonification generally carried out in the conventional process. | 2009-08-06 |
20090196938 | USE OF A MATRIX FOR REMOVING C-REACTIVE PROTEIN FROM BIOLOGICAL FLUIDS - The present invention relates to a method for treating the risk of increased C-reactive protein (CRP) levels by conducting extracorporeal perfusion of blood plasma from patients with risk for cardiovascular diseases or immune dysfunctions, such as autoimmune diseases, through a device, such as a column, which contains absorbent matrix material including lipids, peptides, polypeptides, phosphocholine (PC) or PC derivatives so as to remove C-reactive protein. Moreover, the present invention relates to the use of compounds which have the characteristic to bind CRP at least temporarily, for removing CRP from biological fluids of a patient for prophylaxis and/or treatment of autoimmune diseases, cardiovascular diseases, such as infarction, stroke, diabetes, rheuma and renal failure. | 2009-08-06 |
20090196939 | ANTIMICROBIAL COMPOSITION - A method for antimicrobial treatment (e.g. antimicrobial treatment of food packaging and equipment) comprising applying to microbes a composition containing a diluting solvent (e.g., water), an antimicrobially-active solvent having a density different from the density of the diluting solvent, and an optional cosolvent, surfactant, or additional antimicrobial agent, wherein the amount of antimicrobially-active solvent or additional antimicrobial agent is sufficiently high and the amount of cosolvent or surfactant is sufficiently low so that the composition will provide greater than a 1-log order reduction in the population of bacteria or spores of | 2009-08-06 |
20090196940 | COMPOSITIONS AND METHODS FOR SUPPORTING HEAT SHOCK FUNCTION - Compositions and methods for promoting or maintaining protein accretion in cells, particularly in skeletal muscle cells, by supporting heat shock protein function. The compositions comprise glutamine and additional components directed at enhancing the activity of heat shock proteins. | 2009-08-06 |
20090196941 | Synergistic Phytoceutical Compositions - Phytoceutical compositions for the prevention and treatment of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants from each group. Such combinations have synergistic effects, with minimal side effects. | 2009-08-06 |
20090196942 | TOPICAL COMPOSITIONS CONTAINING CITRUS JABARA EXTRACT - Topical skin care composition comprising an extract of | 2009-08-06 |
20090196943 | Preventing/Treating signs of skin stress/aging by bioenergetically modifying acupuncture points of the face or neck - A regime or regimen for preventing and/or treating the signs of aging and/or stress of the skin, especially for (i) smoothing skin wrinkles and/or relaxing marks on the forehead and/or (ii) tonifying the cheeks, entails topically applying, advantageously via transdermal delivery, onto at least one acupuncture point of the face or the neck of an individual in need of such treatment, notably the acupuncture points PC-1, 6-E, 18-IG, 19-GI, 23-VC, or a restricted area of the face or the neck containing same, at least one bioactive agent modifying the bioenergetic environment at said at least one acupuncture application point and thus mimicking the effects of acupuncture, for example a relaxing/tonifying essential oil. | 2009-08-06 |
20090196944 | Methods of Manufacture of Morinda Citrifolia Based Compositions for Treatment of Anti-Inflammatory Diseases through Inhibition of Cox-1, Cox-2, Interleukin -1beta, Interleukin-6, TNF-alpha, HLE, and iNOS - Methods for manufacturing compositions for inhibiting 5-Lipoxygenase, 15-Lipoxygenase are disclosed. Additionally, methods and compositions for treating and preventing diseases, including inflammatory diseases and cancer are disclosed. Compositions comprising processed | 2009-08-06 |
20090196945 | COMPOSITIONS AND METHODS FOR TREATING BACTERIA - The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compounds (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications. | 2009-08-06 |
20090196946 | STEREOLITHOGRAPHY APPARATUS - A stereolithography apparatus that is configured to fabricate a three-dimensional model by forming a cured layer by irradiating an interface of a photocurable resin with light corresponding to sectional data of the three-dimensional model and stacking the cured layers includes a container holding the photocurable resin and having a constraining window configured to constrain the interface of the photocurable resin; a vertical movement table movable in a vertical direction orthogonal to the interface of the photocurable resin; an optical system configured to form the cured layer between the vertical movement table and the constraining window by irradiating the interface of the photocurable resin with light through the constraining window; and a position constraining mechanism configured to substantially flatten the constraining window by applying a force to the constraining window from the outside of the container when the cured layer is formed by the optical system. | 2009-08-06 |
20090196947 | Continuous metal extruder - A continuous metal extruder that comprises a rotatable member having an extrusion screw portion for transporting metal to be extruded in an axial direction of said rotatable member, and a fixed part, is disclosed. In a method the rotational member and the fixed part are biased in relation to each other. An extruder for carrying out the method comprises a spring element for the biasing. In one embodiment there is a thrust bearing arranged between the rotational member and the fixed part, said thrust bearing has a first bearing race facing said fixed part and a second bearing race facing a part of said rotatable member. The spring element is arranged to bias the thrust bearing, and thereby the rotational member and the fixed part in relation to each other, by exerting along said axial direction an expanding force between at least one of the of the following: the first race of the thrust bearing and the fixed part; and the second race of the thrust bearing and said part of the rotatable member. | 2009-08-06 |
20090196948 | Apparatus for placing mold charges into a compression molding machine - An apparatus for placing a mold charge into a mold of a compression molding machine includes a carrier mounted for rotation around a first axis, at least one arm mounted on the carrier for rotation around a second axis at an angle to the first axis, and a mold charge pick-up cup on the arm for receiving a mold charge, transporting the mold charge and placing the mold charge into a mold of the compression molding machine. A cam is carried in stationary position adjacent to the carrier surrounding the first axis, and a cam follower is operatively coupled to the arm in engagement with the cam for rotating the arm and the mold charge pick-up cup around the second axis as the carrier is rotated around the first axis. The second axis of rotation of the arm preferably is perpendicular to the first axis of rotation of the carrier, and the cam and follower preferably are such that the mold charge pick-up cup is oriented horizontally to receive a mold charge and oriented vertically to deposit the mold charge in the mold of the compression molding machine. A control valve preferably is carried for selective application of vacuum and air under pressure through a passage in the arm to the mold charge pick-up cup to assist in pick-up, transport and deposit of the mold charge into the mold. | 2009-08-06 |
20090196949 | RUMINANT FEED - One or more partial oxidation products of glycerol are reacted with a protein-containing fodder or fodder precursor to provide a rumen undegradable protein-containing ruminant feed product. The reaction may take place more rapidly, or at lower addition levels, or at lower temperatures than is the case when reacting spent sulfite liquor with protein-containing fodder. The partial oxidation products conveniently may be provided as a glycerose liquor containing glycerose and other side products of a glycerol oxidation reaction. The glycerose liquor may in turn conveniently be prepared by partially oxidizing biodiesel-derived glycerol. | 2009-08-06 |
20090196950 | METHODS OF FEEDING PIGS AND PRODUCTS COMPRISING BENEFICIAL FATTY ACIDS - The present invention provides for improved pork products for human consumption and methods of producing such pork products by incorporating healthy lipids containing stearidonic acid into swine feed products. Furthermore, the present invention provides methods for producing said products. In one embodiment of the invention, an animal may be fed feed comprising a transgenic plant product. In other embodiments of the invention, pork meat products for human consumption, such meat products comprising SDA, EPA, and DHA are disclosed. In further embodiments of the invention, pork products comprising novel fatty acid profiles are disclosed. | 2009-08-06 |
20090196951 | Product and Method for Alcoholic Beverage Infused with Resveratrol - This invention relates to the combination of an alcoholic beverage, such as vodka, gin, rum, tequila, whisky, beer, or wine with Resveratrol, an antioxidant and Sirtuin 1 (SIRT1) and PGC-1′ gene activating substance and additives such as sweeteners, masking agents, natural and/or artificial flavoring agents, and/or other additives to eliminate or mitigate any flavoring associated with Resveratrol. | 2009-08-06 |
20090196952 | "GLUTEN-FREE" BLU-VEINED DAIRY PRODUCTS INTENDED FOR PERSONS AFFECTED BY CELIAC DISEASE - The aim of the present invention is “gluten-free” spore or mildew cultures of the genus | 2009-08-06 |
20090196953 | Kimchi container having improved fermentation and ripening function, and kimchi ripening method using the same - Disclosed are a kimchi container with an improved fermentation and ripening function and a kimchi ripening method. The container includes a body and holding unit. The body accommodates kimchi, and includes locking protrusions normally projected from four sides of an inner wall and an opened side to be vacuum-sealed after accommodation of the kimchi. The holding unit includes a contact part having a cross-sectional area corresponding to that of the inner bottom of the body, and through-holes formed in the circumference and at a central region of the upper side. The holding unit further includes locking grooves, to be fitted onto corresponding locking protrusions of the body, formed at an outer wall upwardly extended from and integrally formed with the rim of the contact part. Thereby, tilting of the kimchi container causes the kimchi juice to circulate freely through the holding unit and to return to the kimchi. | 2009-08-06 |
20090196954 | PROCESS FOR THE GRANULATION OF AN ANIMAL FEEDSTUFF ADDITIVE - The invention relates to a process for the granulation of an animal feedstuffs additive comprising amino acids or vitamins in a circulating fluidized bed, wherein the additive is preferably a fermentation product and optionally comprises further constituents from the fermentation broth. | 2009-08-06 |
20090196955 | SHELF-STABLE BEVERAGE COMPOSITION - A shelf-stable, non-refrigerated reduced-calorie beverage that contains about 8 to about 12% fruit juice by volume is provided. The beverage contains at least one nutritive sweetener and at least one non-nutritive sweetener. Preferably, the equivalent sucrose sweetness ratio of the at least one non-nutritive sweetener to all of the total sweeteners is from about 0.35 to about 0.45. Preferably, the at least one non-nutritive sweetener comprises aspartame and acesulfame potassium. | 2009-08-06 |
20090196956 | LOW GLYCEMIC FROZEN CONFECTION - Frozen confections having a combination of ingredients that provide outstanding organoleptic properties while at the same time ensuring a low glycemic product for consumption. In one aspect, the invention provides a frozen confection that comprises a natural nutritive sweetener, wherein the sweetener comprises kiwi, at least one glycoside, and at least one carbohydrate. The subject frozen confection is particularly advantageous because it does not significantly stimulate lipoprotein lipase (LPL), the fat storing enzyme. Moreover, the subject frozen confections are pleasing in taste, mouth-feel, and other organoleptic qualities without the use of artificial sweeteners or sucrose or high glycemic sugar. | 2009-08-06 |
20090196957 | METHODS AND COMPOSITIONS FOR REDUCING SODIUM CONTENT IN FOOD PRODUCTS - The invention provides compositions and methods for reformulating foodstuffs to reduce sodium content, while significantly enhancing salt perception and minimizing additional bitterness. In certain embodiments, the invention provides salt taste enhancing compositions including a blend of three potassium salts—namely, potassium chloride, monopotassium phosphate, and potassium citrate—which, when used in conjunction with sodium chloride, significantly enhances the salt perception in foods and beverages, while imparting no or limited bitter aftertaste. In other embodiments, the invention provides salt taste enhancing compositions including potassium chloride in combination with an organic acid and, optionally, an organic acid salt of potassium. | 2009-08-06 |
20090196958 | Breading and breading mix comprising crunchy corn ingredient, food products created therewith, and methods related thereto - A breading and breading mix comprising a crunchy corn-flavored ingredient, food products created therewith, and methods related thereto, wherein a unique visual experience results from variation in particle size and arrangement, wherein a unique smell and taste experience results from breading flavoring, and from preferred marination processes, and wherein virtually any meat, vegetable or food based product can be adapted into a shelf stable, refrigerated, or frozen Mexican taco-related organoleptic experience. | 2009-08-06 |
20090196959 | Fresh Pineapple Spear Pasteurization Process and Product - A process for producing a fresh pineapple spear package product from fresh whole pineapple is disclosed. The process includes removing the crowns from the fresh whole pineapples; removing surface soil and microbial loads from the fresh whole pineapples; eliminating the rind from the fresh whole pineapples to form peeled fresh pineapples; eliminating the core from the fresh whole pineapples to form cored and peeled fresh pineapples; forming fresh pineapple spears from the cored and peeled fresh pineapples; packaging the fresh pineapple spears in sealed heat-resistant packages to form packaged fresh pineapple spears; and pasteurizing the fresh pineapple spears in the sealed heat-resistant packages to form the fresh pineapple spear package product. | 2009-08-06 |
20090196960 | MICROWAVEABLE PRODUCT - A microwaveable product includes a container having an interior and a fluted first sidewall, the fluted first sidewall including a plurality of flutes extending about the perimeter of the container, a susceptor provided within the interior and having a fluted second sidewall, and a food product provided within the interior, the food product substantially conforming to the shape of the fluted second sidewall. | 2009-08-06 |